Immunosuppression and Tolerance in Adult Liver Transplantation. A literature review on the immunosuppression-drugs after a liver transplantation; how to best provide safe treatment and good quality of life.
AuthorAlmendingen, Tora Elisabeth
Background: There is increasing interest in long-term management issues in liver transplantation recipients; quality of life, complications related to extended immunosuppressants, natural development of co-morbidities and recurrent disease. IS agents are used in induction of the liver transplantation, maintenance of the organ, and reversal of organ rejection. Aim: A systematic literature search with the purpose of summaries the existing clinical research on this specific topic; immunosuppressive medications post-liver transplantation. Material and methods: Search method in PubMed; Medical Subject Headings, with the terms: ("Liver Transplantation"[Mesh]) AND "Immunosuppression" [Mesh]. The selected studies were assessed for scientific quality and relevance for the thesis. Results: Steroid-based IS are responsible for a substantial post-LTx morbidity and mortality, hence, minimization of its use is of utmost importance to improve patient’s quality of life. Because of systemic steroids impact on all organs in the human body and all its side effects that increases risk factors of morbidity. It is important to comprehend the hepatic disease and the patient, as well as understanding the efficacies and side effects/interactions of IS medication. This way the doctor and the patient can strike a balance between suppression of rejection and minimization of side effects. The patient group are very complex, and this have been shown to be a challenge when it comes to comparing the result on the effect of different studies with different immunosuppression’s as the reason for liver failure have a lot to say for graft rejection and patient survival, especially for complication accruing with lifelong IS. Conclusion: LTx recipients are an inherently complex population, with diverse and serious underlying medical concerns that have the potential to adversely affect posttransplant outcomes, thus would a general IS therapy lead to a greater rejection rate. There is a need for more clinical studies, random control trails, that can help us finding the best immunosuppressive treatment for liver transplanted patients.
PublisherUiT Norges arktiske universitet
UiT The Arctic University of Norway
The following license file are associated with this item:
Showing items related by title, author, creator and subject.
Prognostic Impacts of Angiopoietins in NSCLC Tumor Cells and Stroma : VEGF-A Impact Is Strongly Associated with Ang-2 Andersen, Sigve; Dønnem, Tom; Al-Shibli, Khalid Ibrahim; Al-Saad, Samer; Stenvold, Helge; Busund, Lill-Tove; Bremnes, Roy M. (Journal article; Tidsskriftartikkel; Peer reviewed, 2011)Angiopoietins and their receptor Tie-2 are, in concert with VEGF-A, key mediators in angiogenesis. This study evaluates the prognostic impact of all known human angiopoietins (Ang-1, Ang-2 and Ang-4) and their receptor Tie-2, as well as their relation to the prognostic expression of VEGF-A. 335 unselected stage I-IIIA NSCLC-patients were included and tissue samples of respective tumor cells and ...
Humant papillomavirus : en litteraturstudie om HPV, dets relasjon til cancer og tiltak mot videre spredning av virus Gabrielsen, Endre (Master thesis; Mastergradsoppgave, 2012-06-01)I 1983 oppdaget zur Hausen sammenhengen mellom Humant Papillomavirus (HPV) og livmorhalskreft. På denne tiden visste man ikke at det var HPV som var årsaken til at Helaceller kunne leve in vitro. Ny forskning relaterer HPV til en rekke andre cancertyper. En stor andel anal-, oropharyngeal-, penis-, vaginal-, og vulvacancer skyldes HPV. Det er også påvist HPV i tumorvev fra øsofagus, larynx, lunge, ...
Hoem, Gry (Master thesis; Mastergradsoppgave, 2012-06)Fragile X syndrome (FXS) is caused by an expanded CGG repeat (>200 repeats) in the 5’ un-translated portion of the fragile mental retardation 1 gene (FMR1) leading to deficiency or absence of the FMR1 protein (FMRP). FMRP is an RNA carrier protein that controls the translation of a number of other genes that regulate synaptic development and plasticity. Autism occurs in approximately 30% of FXS ...